A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia.

Next Previous
Trial Profile

A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs Arsenic trioxide (Primary) ; Tamibarotene (Primary)
  • Indications Acute promyelocytic leukaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 18 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Mar 2011 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 06 Aug 2010 Planned end date changed from 1 Oct 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top